Viral Diseases

Paid Clinical Trials and Focus Groups


Find Paid Clinical Trials

Paid Clinical Trials - : Viral Diseases

Top of Directory » All Categories » by Illness » Viral Diseases



  • Seneca Valley Virus-001 After Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    Condition:   Lung Cancer
    Interventions:   Biological: Seneca Valley virus-001;   Other: placebo
    Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Safety Study to Assess IV Zanamivir for Treatment of Influenza Infection in Patients Who Are in Hospital

    Conditions:   Influenza A Virus, H1N1 Subtype;   Influenza B Virus;   Influenza, Human;   Influenza, Seasonal
    Intervention:   Drug: zanamivir aqueous solution
    Sponsor:   GlaxoSmithKline
    Not yet recruiting - verified November 2009
  • Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy

    Conditions:   Lymphoma;   Multiple Myeloma;   Influenza A Virus, H1N1 Subtype
    Intervention:   Biological: AS03-adjuvanted H1N1 pandemic influenza vaccine
    Sponsors:   University Health Network, Toronto;   Princess Margaret Hospital, Canada
    Recruiting - verified November 2009
  • Safety, Efficacy and Immunogenicity Study of Fluad Versus Control Vaccines in Unprimed Healthy Children (6 to < 72 Months)

    Condition:   Influenza Disease
    Intervention:   Biological: Influenza virus vaccine: Influenza virus strains A/H1N1, A/H3N2, B
    Sponsors:   Novartis;   Novartis Vaccines
    Recruiting - verified November 2009
  • Safety and Efficacy of BMS-790052 Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)

    Condition:   Hepatitis C Infection
    Interventions:   Drug: BMS-790052;   Drug: BMS-790052;   Drug: Placebo;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Safety and Efficacy of BMS-790052 Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2b and Ribavirin)

    Condition:   Hepatitis C Infection
    Interventions:   Drug: BMS-790052;   Drug: BMS-790052;   Drug: Placebo;   Drug: Peginterferon alfa-2b;   Drug: Ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu

    Conditions:   Pneumonia, Viral;   Influenza A Virus, H1N1 Subtype
    Interventions:   Drug: hydrocortisone;   Drug: isotonic saline
    Sponsors:   University of Versailles;   Assistance Publique - Hôpitaux de Paris
    Not yet recruiting - verified November 2009
  • Study of HF10 in Patients With Refractory Head and Neck Cancer

    Condition:   Refractory Head and Neck Cancer
    Intervention:   Drug: HF10
    Sponsor:   M's Science Corporation
    Recruiting - verified November 2009
  • The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

    Conditions:   Herpesvirus;   Adenovirus;   Cytomegalovirus;   Human Papillomavirus;   Human Polyomavirus;   Respiratory Viruses
    Intervention:  
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified October 2009
  • Study to Determine the Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Who Have Previously Failed Standard of Care

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: BMS-790052;   Drug: BMS-650032;   Drug: pegylated-interferon-α;   Drug: ribavirin
    Sponsor:   Bristol-Myers Squibb
    Not yet recruiting - verified November 2009
  • A Trial to Evaluate the Safety and Immunogenicity of a Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant) in Older Adults

    Condition:   Influenza
    Interventions:   Biological: Investigational Influenza VLP Vaccine 15ug/strain;   Biological: Investigational Influenza VLP Vaccine 60ug/strain;   Biological: TIV
    Sponsor:   Novavax
    Recruiting - verified November 2009
  • Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

    Condition:   Influenza
    Interventions:   Biological: Influenza Virus Vaccine USP Trivalent Types A and B;   Biological: Influenza Virus Vaccine USP Trivalent Types A and B;   Biological: Influenza Virus Vaccine USP Trivalent Types A and B;   Biological: Influenza Virus Vaccine USP Trivalent Types A and B
    Sponsor:   Sanofi-Aventis
    Active, not recruiting - verified November 2009
  • Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults

    Conditions:   Tuberculosis;   HIV Infections
    Interventions:   Biological: AERAS-402;   Biological: Placebo Control
    Sponsors:   Aeras Global Tuberculosis Vaccine Foundation;   Crucell Holland BV
    Not yet recruiting - verified November 2009
  • Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

    Condition:   Hepatitis B, Chronic
    Interventions:   Drug: Entecavir;   Drug: Lamivudine
    Sponsor:   The University of Hong Kong
    Active, not recruiting - verified November 2009
  • Intermittent Versus Continuous Pulse Oximetry Monitoring of Infants Admitted for Bronchiolitis

    Conditions:   Bronchiolitis;   Hypoxia
    Intervention:   Other: Pulse oximetry monitoring
    Sponsors:   Lifespan;   University of Missouri-Columbia
    Not yet recruiting - verified November 2009
  • Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya

    Condition:   HIV Infections
    Interventions:   Other: CARE+ Kenya brief computer risk assessment session;   Other: CARE+ Kenya computer counseling session
    Sponsors:   New York University;   Indiana University;   Moi University
    Not yet recruiting - verified November 2009
  • Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

    Condition:   Sarcoma
    Interventions:   Drug: bortezomib;   Genetic: RNA analysis;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
    Sponsors:   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified November 2009
  • Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection

    Condition:   HIV Infections
    Intervention:   Biological: peptide vaccine (AFO-18)
    Sponsors:   Hvidovre University Hospital;   Statens Serum Institut;   Rigshospitalet, Denmark;   Ministry of the Interior and Health, Denmark
    Enrolling by invitation - verified November 2009
  • Cardiovascular Risk Evaluation and Antiretrovirals in HIV

    Conditions:   Cardiovascular Risk;   HIV Infections
    Intervention:  
    Sponsors:   King's College London;   Guys and St Thomas' Foundation Hospitals Trust
    Completed - verified November 2009
  • Appropriate Timing of HAART in Co-infected HIV/TB Patients

    Conditions:   HIV Infections;   Tuberculosis
    Intervention:   Drug: tenofovir, lamivudine, efavirenz
    Sponsors:   Bamrasnaradura Infectious Diseases Institute;   Mahidol University;   Thai Red Cross AIDS Research Centre
    Recruiting - verified November 2009
  • H1N1v Vaccination of Pregnant Women: A Longitudinal Cohort Study Characterizing Influenza A H1N1v Vaccination in Pregnant Women

    Condition:   H1N1v Influenza
    Interventions:   Biological: Focetria;   Biological: Focetria;   Biological: Focetria;   Biological: Focetria
    Sponsors:   Copenhagen Studies on Asthma in Childhood;   Novartis
    Recruiting - verified November 2009
  • Palivizumab for Prevention of Severe Respiratory Syncytial Virus Infection in Russian Children

    Conditions:   Respiratory Syncytial Infection;   Prematurity;   Bronchopulmonary Dysplasia;   Chronic Heart Disease
    Intervention:   Biological: palivizumab
    Sponsor:   Abbott
    Not yet recruiting - verified November 2009
  • Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients

    Conditions:   HIV-1 Adults Patients;   AIDS;   Triple Class Failure
    Interventions:   Drug: maraviroc;   Drug: Raltegravir;   Drug: Darunavir/ritonavir
    Sponsors:   The Huesped Foundation;   Pfizer
    Not yet recruiting - verified November 2009
  • Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma

    Conditions:   Hepatocellular Carcinoma;   Hepatitis C Virus Chronic Infection
    Intervention:   Biological: CP 675,206
    Sponsors:   Instituto Cientifico y Tecnologico de Navarra, Universidad de Navarra;   Pfizer
    Recruiting - verified November 2009
  • A Spanish-Language Intervention to Enhance Routine HIV Patient Care Delivery [CARE+ Spanish]

    Condition:   HIV Infections
    Interventions:   Other: CARE+ Spanish computer counseling session;   Other: CARE+ Spanish brief computer risk assessment session
    Sponsors:   New York University;   St. Vincent's Medical Center
    Not yet recruiting - verified November 2009
  • Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients

    Condition:   Cytomegalovirus
    Intervention:   Biological: depistage
    Sponsor:   University Hospital, Limoges
    Recruiting - verified November 2009
  • Trial Comparing High Versus Standard Dose Oseltamivir in Severe Influenza Infection in ICU

    Condition:   Influenza A Virus H1N1 Subtype
    Intervention:   Drug: Oseltamivir
    Sponsors:   University of Manitoba;   Hoffmann-La Roche
    Not yet recruiting - verified November 2009
  • Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

    Conditions:   Bird Flu;   Influenza
    Interventions:   Other: Placebo;   Biological: Ad4-H5-Vtn
    Sponsor:   PaxVax, Inc.
    Recruiting - verified November 2009
  • Clinical Trial of Recombinant Hepatitis E Vaccine

    Condition:   Hepatitis E
    Intervention:   Biological: hepatitis E vaccine
    Sponsors:   Xiamen University;   Xiamen Innovax Biotech CO., LTD;   Beijing Wantai Biological Pharmacy Enterprise Co.,Ltd;   National Institute of Diagnostics and Vaccine Development in infectious disease
    Completed - verified November 2009
  • Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly

    Condition:   Influenza
    Interventions:   Biological: Influenza Vaccine;   Biological: Influenza Vaccine
    Sponsor:   Solvay Biologicals
    Not yet recruiting - verified November 2009
  • Safety and Immune Response of One-Dose of Candidate H1N1 Influenza Vaccine GSK2340274A in Adults

    Condition:   Influenza
    Intervention:   Biological: GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A
    Sponsor:   GlaxoSmithKline
    Not yet recruiting - verified November 2009
  • Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

    Condition:   Influenza
    Intervention:   Biological: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
    Sponsor:   Adimmune Corporation
    Active, not recruiting - verified October 2009
  • Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children

    Condition:   Influenza Infection
    Interventions:   Biological: GSK pandemic vaccine GSK2340269A;   Biological: GSK pandemic vaccine GSK2340272A
    Sponsor:   GlaxoSmithKline
    Not yet recruiting - verified November 2009
  • Safety and Efficacy of Reduced Dose Efavirenz (EFV) With Standard Dose EFV Plus Two Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) in Antiretroviral-naïve HIV-infected Individuals.

    Condition:   HIV Infections
    Interventions:   Drug: Efavirenz;   Drug: Efavirenz
    Sponsor:   The National Centre in HIV Epidemiology and Clinical Research
    Not yet recruiting - verified November 2009
  • Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

    Conditions:   Hypertriglyceridemia;   HIV Infection
    Interventions:   Dietary Supplement: Lovaza;   Drug: fosamprenavir/ritonavir
    Sponsors:   Felizarta, Franco, M.D.;   GlaxoSmithKline
    Recruiting - verified November 2009
  • Baclofen to Reduce Alcohol Use in Veterans With HCV

    Conditions:   Hepatitis C;   Alcohol Use Disorders
    Interventions:   Drug: baclofen;   Drug: placebo
    Sponsor:   Department of Veterans Affairs
    Not yet recruiting - verified November 2009
  • An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys

    Condition:   Hepatitis B, Chronic
    Intervention:  
    Sponsor:   Hoffmann-La Roche
    Recruiting - verified November 2009
  • Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

    Conditions:   Liver Cirrhosis;   Hepatitis C Virus;   HIV Infection
    Intervention:   Drug: Pegylated interferon alfa-2a and Ribavirin
    Sponsor:   Sociedad Andaluza de Enfermedades Infecciosas
    Recruiting - verified October 2009
  • Comparison of Different Methods for Reducing Pain From Influenza Vaccine Injections

    Conditions:   Pain;   Anxiety
    Interventions:   Drug: Liposomal lidocaine;   Drug: Vapocoolant spray;   Other: Rubbing adjacent to the injection site;   Other: Distraction
    Sponsor:   The Hospital for Sick Children
    Recruiting - verified October 2009
  • Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1

    Condition:   Chronic Hepatitis C
    Interventions:   Drug: IFN alfa-2b XL 27 MUI + Ribavirin;   Drug: IFN alfa-2b XL 36 MUI + Ribavirin;   Drug: IFN peg alfa-2b 1.5 µg/kg + Ribavirin
    Sponsor:   French National Agency for Research on AIDS and Viral Hepatitis
    Not yet recruiting - verified November 2009
  • Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza

    Conditions:   H1N1 Influenza;   Seasonal Influenza
    Intervention:  
    Sponsor:   Virginia Commonwealth University
    Recruiting - verified November 2009
  • Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

    Condition:   Influenza
    Intervention:   Biological: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
    Sponsor:   Adimmune Corporation
    Active, not recruiting - verified October 2009
  • Vaccination Against Influenza H1N1 in Rheumatic Diseases

    Conditions:   Influenza;   Rheumatic Diseases
    Interventions:   Biological: Focetria (Monovalent MF59-Adjuvanted vaccine);   Biological: Focetria (Monovalent MF59-Adjuvanted vaccine);   Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
    Sponsor:   Tel-Aviv Sourasky Medical Center
    Not yet recruiting - verified November 2009
  • Tolerability and Immunogenicity of Fluval P Monovalent Influenza Vaccine

    Condition:   Influenza
    Interventions:   Biological: Vaccination with Fluval P and Fluval AB influenza vaccines;   Biological: Vaccination with Fluval P monovalent influenza vaccine
    Sponsor:   Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
    Active, not recruiting - verified November 2009
  • Human Anaplasmosis in Eastern France

    Conditions:   Anaplasmosis;   Tick-Borne Disease;   Ehrlichia
    Intervention:   Procedure: Blood sampling
    Sponsor:   University Hospital, Strasbourg, France
    Not yet recruiting - verified November 2009
  • Clinical Trial to Compare the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine to a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

    Condition:   HIV Infections
    Interventions:   Biological: adjuvanted A(H1N1)v influenza vaccine;   Biological: non-adjuvanted A(H1N1)v influenza vaccine
    Sponsors:   French National Agency for Research on AIDS and Viral Hepatitis;   GlaxoSmithKline
    Active, not recruiting - verified November 2009
  • A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK7009

    Condition:   Hepatitis C
    Intervention:   Drug: MK7009
    Sponsor:   Merck
    Recruiting - verified November 2009
  • The Effect of Fact Versus Myth Messages on Receipt of Influenza Vaccination

    Condition:   Influenza Vaccination
    Interventions:   Behavioral: Fact Only Education Message;   Behavioral: Fact and Myth Educational Message;   Behavioral: Fact, Myth, Why Educational Message;   Behavioral: Control Educational Message
    Sponsor:   Northwestern University
    Enrolling by invitation - verified November 2009
  • Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

    Conditions:   Hematopoietic/Lymphoid Cancer;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large-Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Chronic Lymphocytic Leukemia;   Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Lymphoma, Mucosa-Associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-Cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Other: fluorescence in situ hybridization;   Other: flow cytometry;   Other: RNA analysis;   Other: laboratory biomarker analysis;   Other: cytogenetic analysis;   Other: polymerase chain reaction
    Sponsor:   Fred Hutchinson Cancer Research Center
    Not yet recruiting - verified November 2009
  • Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

    Condition:   Chronic Hepatitis C Virus Infection
    Interventions:   Drug: PEG-rIL-29;   Drug: Peginterferon alfa-2a;   Drug: Ribavirin
    Sponsors:   ZymoGenetics;   Bristol-Myers Squibb
    Recruiting - verified October 2009
    • Menu
    Find Paid Clinical Trials